- Home
- JJSF vs MIRM Comparison
JJSF vs MIRM Comparison
Compare JJSF & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JJSF
- MIRM
- Stock Information
- Founded
- JJSF 1971
- MIRM 2018
- Country
- JJSF United States
- MIRM United States
- Employees
- JJSF N/A
- MIRM N/A
- Industry
- JJSF Specialty Foods
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- JJSF Consumer Staples
- MIRM Health Care
- Exchange
- JJSF Nasdaq
- MIRM Nasdaq
- Market Cap
- JJSF N/A
- MIRM 2.5B
- IPO Year
- JJSF N/A
- MIRM 2019
- Fundamental
- Price
- JJSF $116.61
- MIRM $52.66
- Analyst Decision
- JJSF Buy
- MIRM Strong Buy
- Analyst Count
- JJSF 2
- MIRM 9
- Target Price
- JJSF $142.50
- MIRM $66.22
- AVG Volume (30 Days)
- JJSF 190.1K
- MIRM 465.4K
- Earning Date
- JJSF 08-04-2025
- MIRM 08-06-2025
- Dividend Yield
- JJSF 2.66%
- MIRM N/A
- EPS Growth
- JJSF N/A
- MIRM N/A
- EPS
- JJSF 3.89
- MIRM N/A
- Revenue
- JJSF $1,585,410,000.00
- MIRM $379,251,000.00
- Revenue This Year
- JJSF $3.64
- MIRM $35.83
- Revenue Next Year
- JJSF $3.68
- MIRM $16.83
- P/E Ratio
- JJSF $29.98
- MIRM N/A
- Revenue Growth
- JJSF 0.49
- MIRM 69.31
- 52 Week Low
- JJSF $109.71
- MIRM $36.17
- 52 Week High
- JJSF $180.80
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- JJSF 50.81
- MIRM 64.66
- Support Level
- JJSF $115.10
- MIRM $49.22
- Resistance Level
- JJSF $119.24
- MIRM $53.86
- Average True Range (ATR)
- JJSF 3.23
- MIRM 1.57
- MACD
- JJSF 0.43
- MIRM 0.08
- Stochastic Oscillator
- JJSF 58.10
- MIRM 79.63
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.